Kakao Healthcare said over 50 health regulatory officials, including those from the Ministry of Food and Drug Safety, the WHO, and the U.S. FDA, visited its headquarters on Monday in light of the AI Regulatory and International Symposium 2024 (AIRIS 2024).

The event is ongoing at the Shilla Seoul Hotel from Monday to Thursday. The symposium seeks to foster international collaboration and innovation in the development and regulation of AI-enhanced medical products.

Notable attendees included Sameer Pujari, the AI Lead from the World Health Organization (WHO), David Reese, the Executive Vice President and Chief Technology Officer of the global pharmaceutical company Amgen, and officials from the FDA.

During the visit, Kakao Healthcare CEO Hwang Hee demonstrated Kakao Healthcare's AI-based mobile blood sugar management service, PASTA, which was launched on Feb. 1.

Hwang elaborated on its key features and benefits, emphasizing the company's commitment to leveraging AI in healthcare.

Hwang also highlighted Kakao Healthcare's medical big data analysis solutions and collaborative research models based on Real-World Evidence (RWE) and Real-World Data (RWD).

Among the showcased collaborations was a precision beauty solution developed with L'Oréal, utilizing RWE.

"We are actively developing various smart healthcare products using AI and conducting research to improve technologies based on RWE and RWD," Hwang said. "We will continue to be a leader in the healthcare industry by applying AI to software medical devices and collaborating with global companies."